Associations of circulating HMGB1 levels with diabetes in full adjusted models.

<p>OR, odds ratio; CI, confidence interval; BMI, body mass index;SBP, systolic blood pressure; DBP, diastolic blood pressure;TC, total cholesterol; TG, triglyceride; HDL-c, high-density lipoprotein-cholesterol; LDL-c, low-density lipoprotein-cholesterol.</p><p>Associations of circulating HMGB1 levels with diabetes in full adjusted models.</p

Plasma HMGB1 concentrations.

<p>A. Comparison of HMGB1 concentrations in NGT, T2DM, NW and OB groups. B. Comparison of HMGB1 concentrations in NGT-NW, NGT-OB, T2DM-NW and T2DM-OB subgroups. aP < 0.001 compared with NGT. bP < 0.001 compared with NW. cP < 0.01 compared with NGT-NW. dP < 0.001 compared with NGT-OB. eP < 0.001 compared with T2DM-NW.</p

Plasma HMGB-1 Levels in Subjects with Obesity and Type 2 Diabetes: A Cross-Sectional Study in China

<div><p>Object</p><p>To detect the levels of plasma High-Mobility Group Box-1(HMGB1) in Chinese subject with obesity and type 2 diabetes mellitus (T2DM), and to investigate the correlations between plasma HMGB1 concentration and parameters of body fat, insulin resistance (IR) metabolism and inflammation.</p><p>Methods</p><p>This study recruited 79 normal glucose tolerance (NGT) subjects and 76 newly diagnosed T2DM patients. NGT and T2DM groups were divided into normal weight (NW) and obese (OB)subgroups respectively. Anthropometric parameters such as height, weight, waist circumference, hip circumference and blood pressure were measured. Plasma concentrations of HMGB1, IL-6, fasting plasma glucose (FPG), 2 hours post challenge plasma glucose (2hPG), serum lipid, glycated hemoglobin (HbA_1C) and fasting insulin (FINS) were examined. The homeostasis model assessment (HOMA) was performed to assess IR status.</p><p>Results</p><p>Plasma HMGB1 levels were higher in T2DM group than that in NGT group. The concentrations of serum HMGB1 were also higher in subjects with OB than those in subjects with NW both in NGT and T2DM groups. Plasma levels of HMGB1 were positively correlated with waist hip ratio (WHR), blood pressure, FPG, FINS, HOMA-IR, TG, IL-6 and negatively correlated with HOMA-βand high-density lipoprotein-cholesterol (HDL-c) independent of age, gender and BMI. Plasma levels of HMGB1 were significantly correlated with diabetes in fully adjusted models.</p><p>Conclusion</p><p>Plasma HMGB1 levels were increased in Chinese subjects with pure T2DM, which might be caused by IR. Serum HMGB1 participated in the pathological process of obesity and T2DM via its proinflammatory effect.</p></div

Clinical and laboratory characteristics of the study subjects.

<p>Data are presented as means±SD. NGT, normal glucose tolerance; T2DM, type 2 diabetes mellitus; NW, normal weight; OB, obesity; BMI, body mass index; Wc, waist circumference; WHR, waist hip ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; 2hPG, 2 hours postchallenge plasma glucose; HbA_1C, glycated hemoglobin; FINS, fasting serum insulin; HOMA-IR, Homeostasis Model Assessment for insulin resistance; HOMA-β, Homeostasis Model Assessment for beta-cell function; TC, total cholesterol; TG, triglyceride; HDL-c, high-density lipoprotein-cholesterol; LDL-c, low-density lipoprotein-cholesterol; IL-6, interleukin- 6.</p><p>^aP<0.05 compared with NGT-NW,</p><p>^bP<0.05 compared with T2DM-NW,</p><p>^cP<0.05 compared with NGT-OB,</p><p>^dP<0.01 compared with NGT-NW,</p><p>^eP<0.01 compared with T2DM-NW,</p><p>^fP<0.01 compared with NGT-OB.</p><p>Clinical and laboratory characteristics of the study subjects.</p

Partial correlations analysis of variables associated with circulating HMGB1 concentration in study population.

<p>BMI, body mass index; Wc, waist circumference; WHR, waist hip ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; 2hPG, 2h postchallenge plasma glucose; HbA_1C, glycated hemoglobin; FINS, fasting serum insulin; HOMA-IR, Homeostasis Model Assessment for insulin resistance; HOMA-β, Homeostasis Model Assessment for beta-cell function; TC, total cholesterol; TG, triglyceride; HDL-c, high-density lipoprotein-cholesterol; LDL-c, low-density lipoprotein-cholesterol; IL-6, interleukin- 6.</p><p>Partial correlations analysis of variables associated with circulating HMGB1 concentration in study population.</p

Copper-Catalyzed, C–C Coupling-Based One-Pot Tandem Reactions for the Synthesis of Benzofurans Using <i>o</i>‑Iodophenols, Acyl Chlorides, and Phosphorus Ylides

One-pot reactions involving acyl chlorides, phosphorus ylides, and <i>o</i>-iodophenols with copper catalysis have been established for the rapid synthesis of functionalized benzofurans. With all of these easily available and stable reactants, the construction of the target products has been accomplished via tandem transformations involving a key C–C coupling, leading to the formation of one C­(sp²)–C bond, one C­(sp²)–O bond, and one CC bond

DataSheet_1_The Immune Subtype Contributes to Distinct Overall Survival for Ovarian Cancer Patients With Platinum-Based Adjuvant Therapy.docx

ObjectiveNowadays, platinum-based therapy has been widely used as the first-line therapy of ovarian cancer. However, the effect of the tumor microenvironment on platinum-based therapy remains unclear. In this study, we aim to investigate the relationship between immune microenvironment subtypes and the prognosis of platinum-based therapy in ovarian cancer.MethodsWe integrated 565 ovarian cancer samples from two datasets and obtained the immune subtypes (ISs) by consistent clustering of 1190 immune-related gene expressions. The proportional hazards regression model was used to assess the relationship between ISs and the prognosis of platinum-based adjuvant therapy including progression-free survival (PFS) and overall survival (OS). The prognostic contribution of ISs was validated in three additional cohorts. Non-parametric tests were used to assess genomic characteristics, the proportion of immune cells, and immune-related signature differences among ISs.ResultsWe identified and validated five ISs associated with different clinical outcomes of the platinum-based adjuvant therapy in ovarian cancer patients. These differences were only found in OS rather than PFS. An immune subtype had the worst OS. Those patients mainly derived from the mesenchymal subtype had the lowest tumor purity with a high leukocyte fraction as well as stromal fraction and had the highest TGF-β response signaling. By contrast, an immune subtype characterized by immunoreactive status with the highest CD8+T cell infiltration and elevated IFN-γ response signaling had the best prognosis. Other subtypes with more diverse immunologic features such as lowest macrophage regulation signaling showed intermediate prognoses. Notably, the contribution of ISs to OS was independent of the clinical response to platinum-based drugs.ConclusionOur analysis revealed the association between different immune characteristics and platinum-based adjuvant therapy, indicating the combination of ISs and chemotherapy could optimize the treatment strategy of OC patients.</p

3D fractal gradient of the architectural form for the different directions in Zhengzhou City.

3D fractal gradient of the architectural form for the different directions in Zhengzhou City.</p

Table_5_The Immune Subtype Contributes to Distinct Overall Survival for Ovarian Cancer Patients With Platinum-Based Adjuvant Therapy.xlsx

ObjectiveNowadays, platinum-based therapy has been widely used as the first-line therapy of ovarian cancer. However, the effect of the tumor microenvironment on platinum-based therapy remains unclear. In this study, we aim to investigate the relationship between immune microenvironment subtypes and the prognosis of platinum-based therapy in ovarian cancer.MethodsWe integrated 565 ovarian cancer samples from two datasets and obtained the immune subtypes (ISs) by consistent clustering of 1190 immune-related gene expressions. The proportional hazards regression model was used to assess the relationship between ISs and the prognosis of platinum-based adjuvant therapy including progression-free survival (PFS) and overall survival (OS). The prognostic contribution of ISs was validated in three additional cohorts. Non-parametric tests were used to assess genomic characteristics, the proportion of immune cells, and immune-related signature differences among ISs.ResultsWe identified and validated five ISs associated with different clinical outcomes of the platinum-based adjuvant therapy in ovarian cancer patients. These differences were only found in OS rather than PFS. An immune subtype had the worst OS. Those patients mainly derived from the mesenchymal subtype had the lowest tumor purity with a high leukocyte fraction as well as stromal fraction and had the highest TGF-β response signaling. By contrast, an immune subtype characterized by immunoreactive status with the highest CD8+T cell infiltration and elevated IFN-γ response signaling had the best prognosis. Other subtypes with more diverse immunologic features such as lowest macrophage regulation signaling showed intermediate prognoses. Notably, the contribution of ISs to OS was independent of the clinical response to platinum-based drugs.ConclusionOur analysis revealed the association between different immune characteristics and platinum-based adjuvant therapy, indicating the combination of ISs and chemotherapy could optimize the treatment strategy of OC patients.</p

Gradient and direction analysis.

Gradient and direction analysis.</p